However, when incubated in AATD patient plasma, the activity footprint generated was significantly greater at 64.5 nM (59.2–70.2) for PR3 (versus healthy plasma p < 0.05 and COPD plasma p < 0.001) and 8.3 nM (6.6–12.0) for NE (versus healthy p < 0.05 versus COPD p = 0.05). This evidence concerns the gene PRTN3 and chronic obstructive pulmonary disease.